VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Verrica Pharmaceuticals Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.44−0.16 (-4.31%)
Close on Oct 19, 2026
- Market cap
- $73.29M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Gross margin
–
Operating margin
-34.2%
Net margin
-50.3%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +370.2% | +57.9% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -87.1% | -240.4% | |
| Return on assets | – | -59.9% | -35.3% | |
| Current ratio | – | 1.71 | 2.59 | |
| Interest coverage | – | -13.2× | -1.6× | |
| Inventory turnover | – | – | – | |
| Capex to revenue | – | – | 0.0% | |
| Diluted shares | – | 2M | 11M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Verrica Pharmaceuticals generated $163.36M from operations and spent $1.57M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$163.36M
Used
$1.57M
Capital expenditure$1.57M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-50.3%
×Asset turnover0.70×
×Equity multiplier6.80×
=Return on equity, FY2025-240.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -50.3% | 0.70× | 6.80× | -240.4% |
| FY2024 | -1012.1% | 0.11× | 13.71× | -1546.6% |
| FY2023 | -1307.5% | 0.08× | 2.11× | -224.1% |
| FY2022 | -271.1% | 0.14× | 1.72× | -67.4% |
| FY2021 | -292.3% | 0.16× | 2.35× | -107.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$17.89M
- Cash generatingOperating cash flow above zero-$17.63M
- Return on assets improvedROA up on the prior year-93.9% → -33.0%
- Earnings backed by cashOperating cash flow above net income-$17.63M vs -$17.89M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.76 → 2.59
- No dilutionShare count did not rise5M → 11M
- Gross margin improvedGross margin up on the prior year65.64% → –
- More efficientAsset turnover rose0.09 → 0.66